Assembly Biosciences, Inc. (NASDAQ:ASMB) – Analysts at William Blair boosted their FY2017 earnings estimates for Assembly Biosciences in a research note issued to investors on Monday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of ($2.95) per share for the year, up from their previous estimate of ($3.40). William Blair also issued estimates for Assembly Biosciences’ Q4 2017 earnings at ($0.66) EPS, FY2018 earnings at ($3.18) EPS and FY2019 earnings at ($3.55) EPS.

A number of other equities research analysts also recently commented on ASMB. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Thursday, August 3rd. Jefferies Group LLC started coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 target price for the company. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Wednesday. Finally, Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th.

TRADEMARK VIOLATION NOTICE: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/17/assembly-biosciences-inc-expected-to-earn-fy2017-earnings-of-2-95-per-share-asmb.html.

Shares of Assembly Biosciences (ASMB) traded up $1.82 during midday trading on Wednesday, hitting $34.95. 82,300 shares of the stock were exchanged, compared to its average volume of 84,357. Assembly Biosciences has a 1-year low of $11.07 and a 1-year high of $36.31.

In related news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total value of $29,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.60% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in ASMB. Nationwide Fund Advisors purchased a new stake in Assembly Biosciences during the second quarter worth approximately $161,000. Parametric Portfolio Associates LLC grew its stake in Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 1,203 shares during the period. Legal & General Group Plc purchased a new stake in Assembly Biosciences during the second quarter worth approximately $212,000. Wells Fargo & Company MN purchased a new stake in Assembly Biosciences during the second quarter worth approximately $213,000. Finally, Trexquant Investment LP purchased a new stake in Assembly Biosciences during the second quarter worth approximately $217,000. Hedge funds and other institutional investors own 62.19% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.